
AnHeart Therapeutics develops and commercializes innovative pharmaceuticals, focusing on the ROS1/NTRK inhibitor, AB-106.
AnHeart Therapeutics, founded with a mission to improve human health and quality of life, specializes in developing and commercializing innovative pharmaceutical products. The company focuses on precision oncology therapeutics, particularly targeting cancer treatments. Their flagship product, AB-106, is an oral, highly selective ROS1/NTRK small molecule inhibitor designed to treat specific types of cancer. AnHeart Therapeutics aims to address unmet medical needs in the oncology market by advancing their pipeline of novel therapies.
Notable figures associated with AnHeart Therapeutics include its affiliation with Nuvation Bio, a prominent biopharmaceutical company. Key achievements include the development of clinical-stage assets such as Taletrectinib, a ROS1 inhibitor for non-small cell lung cancer, and Safusidenib, an mIDH1 inhibitor for various tumors. The company's impact is marked by its commitment to precision medicine, offering hope to cancer patients through targeted therapeutic options.

Anthos Therapeutics

Palm Therapeutics

Ascenta Therapeutics

Hengrui Therapeutics

OncXerna Therapeutics
oncxerna.com

Athenex

Anji Pharmaceuticals

Nested Therapeutics
nestedtx.com
Anapneo Therapeutics

Anthera Pharmaceuticals
anthera.com

Angarus Therapeutics
angarustx.com

Angion
elicio.com

Onchilles Pharma

Alphina Therapeutics

Cardurion Pharmaceuticals
Companies similar to AnHeart Therapeutics include Anthos Therapeutics, Palm Therapeutics, Ascenta Therapeutics and Hengrui Therapeutics.
AnHeart Therapeutics was founded in 2018.
AnHeart Therapeutics' headquarters is located in New York City, NY, US.
AnHeart Therapeutics' most recent funding round was for $61M (USD) in December 2021.
As of Dec 14, 2021, AnHeart Therapeutics has raised a total of $75.6M (USD).